You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD30-positive

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, T-Cell, Cutaneous Trial in New York (AFM13)

Completed
  • Lymphoma, T-Cell, Cutaneous
  • New York, New York
    Center for Lymphoid Malignancies
Jul 14, 2020

Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma Trial in Worldwide (Brentuximab

Completed
Has Results
  • Primary Cutaneous Anaplastic Large Cell Lymphoma
  • +2 more
  • Brentuximab Vedotin
  • +2 more
  • Los Angeles, California
  • +40 more
Dec 16, 2020

Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

Recruiting
  • Lymphoma
  • +7 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

Lymphoma, Relapse/Recurrence Trial in Wuhan, Nanchang (CD30 CAR-T, Camrelizumab)

Recruiting
  • Lymphoma
  • Relapse/Recurrence
  • Wuhan, Hubei, China
  • +1 more
Apr 8, 2022

Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma Trial in Hangzhou (CTA30X)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Non-hodgkin Lymphoma
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
Dec 25, 2020

Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory Trial in United States (CD30.CAR-T, Fludarabine,

Active, not recruiting
  • Hodgkin Lymphoma, Adult
  • +3 more
  • Duarte, California
  • +4 more
Apr 3, 2022

Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified Trial in Hangzhou (Anti CD30 CAR-T Cell Injection)

Not yet recruiting
  • Hodgkin Lymphoma
  • +7 more
  • Anti CD30 CAR-T Cell Injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of medicine, Zhejiang Uni
Jan 12, 2022

Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning)

Active, not recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +2 more
  • Valhalla, New York
    New York Medical College
Oct 24, 2022

Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Lymphoma
  • CD70-targeting CAR-T cells
  • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 9, 2023

Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Solid Tumor, Adult
  • CD70-targeting CAR-T cells
  • Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 8, 2023

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)

Recruiting
  • CD70-positive Advanced Urologic Neoplasms
  • Anti-CD70 CAR-T cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Aug 11, 2023

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)

Recruiting
  • Peripheral T Cell Lymphoma
  • ATLCAR.CD30 T cells
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
Mar 4, 2022

COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)

Active, not recruiting
  • COL6A3 Positive
  • +3 more
  • Aldesleukin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in Chapel Hill, Houston (CAR.CD30 T cells)

Active, not recruiting
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Lymphoma
  • CAR.CD30 T cells
  • Chapel Hill, North Carolina
  • +2 more
Mar 16, 2022

Hematologic Diseases, Tumors Trial in Hangzhou (CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation)

Recruiting
  • Hematologic Diseases
  • Neoplasms
  • CD7 CAR-T cells injection
  • Allogeneic hematopoietic stem cell transplantation
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 11, 2023

Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer Trial in Nanchang (CD70 CAR-T cells)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • CD70 CAR-T cells
  • Nanchang, Jiangxi, China
    The First Affiliated Hospital of Nanchang University
Aug 23, 2023

Advanced or Metastatic Solid Tumors Trial in Beijing (CD40 ligand expressing MSLN-CAR T cells, Albumin-bound paclitaxel,

Recruiting
  • Advanced or Metastatic Solid Tumors
  • CD40 ligand expressing MSLN-CAR T cells
  • +2 more
  • Beijing, Beijing, China
    Kaichao Feng
Jan 19, 2023

Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Houston (autologous CAR.CD30 EBV specific-CTLs)

Active, not recruiting
  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • autologous CAR.CD30 EBV specific-CTLs
  • Houston, Texas
  • +1 more
Feb 4, 2022

Relapsed or Refractory EBV-and CD30-positive Lymphomas Trial in Seongnam, Seoul (brentuximab vedotin)

Completed
  • Relapsed or Refractory EBV-and CD30-positive Lymphomas
  • brentuximab vedotin
  • Seongnam, Korea, Republic of
  • +2 more
Oct 31, 2019

Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CD19 specific Chimeric Antigen Receptor T Cell
  • Columbus, Ohio
    Nationwide Children's Hospital
Mar 9, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • Cyclophosphamide (Non-IMP, Lymphodepletion)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +4 more
Jul 24, 2023

Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous

Recruiting
  • Classical Hodgkin Lymphoma
  • +2 more
  • Duarte, California
  • +4 more
Jun 27, 2022